Bibliographie : Cannabinoïdes et Epilepsie Docteur Christian SUEUR, GRECC, version actualisée, mars 2020
Lire la suiteCannabinoid and Terpenoid Doses are Associated with Adult ADHD Status of Medical Cannabis Patients Jeffrey Y. Hergenrather, Joshua Aviram, Yelena Vysotski, Salvatore Campisi-Pinto, Gil M. Lewitus and David Meiri. Rambam Maimonides Medical Journal, 2020, 11, (1), e0001 Doi : 10.5041/RMMJ.10384 Methods : Participants were adult patients licensed for medical cannabis (MC) treatment who also reported a diagnosis of ADHD by a physician. Data on demographics, ADHD, sleep, and anxiety were collected using self-report questionnaires. Data collected on MC treatment included administration route, cultivator, cultivar name, and monthly dose. Comparison statistics were used to evaluate differences in reported parameters between low (20–30 g, n=18) and [...]
Lire la suiteIs There a Role for Cannabis in Mental Health Disorders ? Pauline Anderson & Charles P. Vega, Medscape, CME / ABIM MOC / CE Released : 12/13/2019 https://www.medscape.org/viewarticle/922367 Clinical Context The most common indication for the use of medicinal cannabis is pain, although the results of studies of cannabis products for chronic pain are mixed. Häuser and colleagues performed a review of systematic reviews of cannabis for chronic pain conditions, and their results were published in the October 15, 2017 issue of European Journal of Pain.[1] Reviewers evaluated 10 systematic reviews of cannabis for pain. Methodological quality was high in 4 of the reviews. There was [...]
Lire la suiteCannabidiol treatment in an adolescent with multiple substance abuse, social anxiety and depression. Case Report Clarissa Laczkovics · Oswald D. Kothgassner · Anna Felnhofer · Claudia M. Klier Neuropsychiatrie, 2020, 4 p. Doi : 10.1007/s40211-020-00334-0 Summary In this report, we present a case of a 16,9- year-old patient with multiple substance use disorder (cannabis, MDMA, cocaine, ecstacy), severe depression, social phobia and narcissistic personality disorder. We administered Cannabidiol (CBD) capsules in different dosages (starting dosage 100 mg up to 600 mg over 8 weeks) after unsuccessful treatment with antidepressants. CBD was a safe and well tolerated medication for this patient. Upon treatment with CBD and [...]
Lire la suiteWhat Should I KnowAboutMedical Cannabis ? Michael A. Incze, MD, MSEd; Deepika Slawek, MD,MS, MPH; Chinazo O. Cunningham, MD,MS The JAMA Internal Medicine Patient Page, Online : February 11, 2020 doi : 10.1001/jamainternmed.2020.0018 What Is Cannabis and How Is It Used ? • Cannabis (ie, marijuana) is a plant that contains a complex mixture of chemicals called cannabinoids. Examples of cannabinoids include tetrahydrocannabinol (THC) and cannabidiol (CBD). • Whereas THC is primarily responsible for the psychoactive effects (euphoria) of cannabis, CBD may decrease pain but causes far fewer psychoactive effects than THC. • Cannabis is used medically as purified cannabinoids (eg, CBD), synthetic cannabinoids (eg, dronabinol), or [...]
Lire la suitePsychedelics and potential benefits in “healthy normals”: A review of the literature Sam GANDY Journal of Psychedelic Studies, 2019, 3, (3), 280–287. Doi : 10.1556/2054.2019.029 We are in the midst of a psychedelic research renaissance. With research examining the efficacy of psychedelics as a treatment for a range of mental health indications still in its early stages, there is an increasing body of research to show that careful use of psychedelics can yield a variety of benefits in “healthy normals” and so lead to “the betterment of well people.” Psychedelics have been found to modulate neuroplasticity, and usage in a supportive setting can result [...]
Lire la suiteLe cannabidiol, un agent thérapeutique prometteur ? Benjamin Rolland , Mathieu Chappuy, Patrizia Carrieri SWAPS, 3e et 4e trimestre 2019, n° 92-93, , 5-6. Deuxième cannabinoïde le plus étudié après le THC, sans effet psychoactif, le cannabidiol dispose de propriétés thérapeutiques intéressantes, notamment en psychiatrie. Le point sur les recherches La grande famille des cannabinoïdes Les cannabinoïdes sont un ensemble de substances capables d’activer les récepteurs du même nom (« récepteurs cannabinoïdes »). Il existe deux grandes familles de récepteurs cannabinoïdes, CB1 et CB2. Dans le système nerveux central, c’est surtout CB1 qui est exprimé, alors que CB2 est principalement présent dans le système immunitaire. [...]
Lire la suiteMedicinal cannabis for psychiatric disorders: a clinically-focused systematic review Jerome Sarris, Justin Sinclair, Diana Karamacoska, Maggie Davidson and Joseph Firth BMC Psychiatry, 2020, 20, 24, 1-14. Doi : 10.1186/s12888-019-2409-8 Abstract Background : Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes. Medicinal cannabis has been reported to have potential efficacy in reducing pain, muscle spasticity, chemotherapy-induced nausea and vomiting, and intractable childhood epilepsy. Yet its potential application in the field of psychiatry is lesser known. Methods : The first clinically-focused systematic review on the emerging medical application of cannabis across all major psychiatric disorders was conducted. Current evidence regarding [...]
Lire la suiteCadre de l’expérimentation du cannabis à usage médical https://www.ansm.sante.fr/Dossiers/Cannabis-a-usage-medical/Cadre-de-l-experimentation-du-cannabis-a-usage-medical/(offset)/1 L’expérimention du cannabis à usage médical sera lancée au deuxième semestre 2020. L’objectif principal de cette phase expérimentale est d’évaluer en situation réeller le circuit de prescription et délivrance ainsi que l’adhésion des professionnels de santé et des patients à ces conditions. Son objectif secondaire est de recueillir des premières données françaises d’efficacité et de sécurité. Les éléments les plus importants de ce cadre visent à sécuriser au mieux la prescription et le suivi des patients : Sécurisation de la prescription : le traitement ne pourra être initié que par des médecins qui exercent dans [...]
Lire la suiteCannabis for Sleep: Short-Term Benefit, Long-Term Disruption ? Michael Vlessides Medscape, January 24, 2020 https://www.medscape.com/viewarticle/924202_print Patients suffering from chronic pain who take medicinal cannabis to initiate and maintain sleep appear to experience short-term benefit, but long-term use may ultimately disrupt slumber, new research shows. Investigators found whole-plant medical cannabis use was associated with fewer problems with respect to waking up at night, but they also found that frequent medical cannabis use was associated with more problems initiating and maintaining sleep. "Cannabis may improve overall sleep in the short term," study investigator Sharon Sznitman, PhD, University of Haifa Faculty of Social Welfare and Health Sciences in Israel, [...]
Lire la suite